Didanosine - PharmaKB

Didanosine

Videx (didanosine) is a small molecule pharmaceutical. Didanosine was first approved as Videx on 1991-10-09. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA.

Download report

Favorite

BMS

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
urogenital diseases	D000091642
immune system diseases	D007154

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Didanosine

Tradename	Company	Number	Date	Products
VIDEX	Bristol Myers Squibb	N-020156 DISCN	1991-10-09	1 products, RLD
VIDEX	Bristol Myers Squibb	N-020154 DISCN	1991-10-09	5 products, RLD
VIDEX	Bristol Myers Squibb	N-020155 DISCN	1991-10-09	4 products
VIDEX EC	Bristol Myers Squibb	N-021183 DISCN	2000-10-31	4 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
didanosine	ANDA	2012-05-02

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
hiv infections	EFO_0000764	D015658	B20
acquired immunodeficiency syndrome	EFO_0000765	D000163	B20

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J05: Antivirals for systemic use

— J05A: Direct acting antivirals

— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors

— J05AF02: Didanosine

HCPCS

Code	Description
S0137	Didanosine (ddi), 25 mg

Clinical

Clinical Trials

381 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv infections	D015658	EFO_0000764	B20	9	23	6	1	12	50
Acquired immunodeficiency syndrome	D000163	EFO_0000765	B20	2	5	1	2	6	16
Infections	D007239	EFO_0000544	—	1	7	—	1	2	11

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv	D006678	—	—	—	—	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Communicable diseases	D003141	—	—	1	2	—	—	2	5
Aids-related complex	D000386	EFO_0007137	B20	—	1	—	—	2	3
Sarcoma	D012509	—	—	1	1	—	—	—	2
Kaposi sarcoma	D012514	—	C46	1	1	—	—	—	2
Leukoencephalopathies	D056784	HP_0002352	—	—	1	—	—	1	2
Progressive multifocal leukoencephalopathy	D007968	EFO_0007455	A81.2	—	1	—	—	1	2
Dementia	D003704	EFO_0003862	F03	—	1	—	—	—	1
Aids dementia complex	D015526	EFO_0002608	—	—	1	—	—	—	1
Neoplasms	D009369	—	C80	1	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hiv seropositivity	D006679	—	—	1	—	—	—	—	1
Alzheimer disease	D000544	EFO_0000249	F03	1	—	—	—	—	1
Pregnancy	D011247	EFO_0002950	Z33.1	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Immunologic deficiency syndromes	D007153	HP_0002721	D84.9	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Didanosine
INN	didanosine
Description	Didanosine is a purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS. It has a role as an antimetabolite, a HIV-1 reverse transcriptase inhibitor, an antiviral drug, an EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor and a geroprotector.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1